The Global Sickle Cell Anemia Testing & Screening Market Size valued for USD 226 Million in 2021 and is anticipated to reach USD 383 Million by 2030 with a CAGR of 6.1% from 2022 to 2030.

A genetic condition known as sickle cell anemia impairs the body's capacity to manufacture normal hemoglobin, a protein present in red blood cells that aids in the transportation of oxygen throughout the body. Red blood cells in persons with sickle cell anemia have a sickle- or crescent-shaped appearance due to defective hemoglobin. These aberrant cells frequently obstruct blood arteries, which can result in excruciating pain, tissue damage, and other issues. A change in the HBB gene, which gives instructions for creating the beta-globin portion of hemoglobin, results in sickle cell anemia. A single point mutation that leads in the replacement of one amino acid for another in the beta-globin subunit is what causes the disease's most prevalent Technology.

Hemoglobin electrophoresis, a blood test, is used to identify sickle cell anemia. This test distinguishes between various hemoglobin types, enabling the physician to spot aberrant hemoglobin, such as sickle hemoglobin (HbS). The test can be carried out at any age if a person exhibits symptoms of sickle cell anemia or has a family history of the condition. It is frequently done as part of a newborn screening programme.

A different test known as HPLC, or High Performance Liquid Chromatography, is moreover employed to find the aberrant kind of hemoglobin. This method enables a more thorough and precise investigation of the presence of distinct hemoglobin variations by classifying the various forms of hemoglobin according to their charge, size, and shape.

Sickle Cell Anemia Testing & Screening Market Dynamics

As more children are born to parents who are genetically predisposed to the condition, the number of persons with sickle cell anemia is rising. This element is anticipated to increase demand for sickle cell anemia testing and diagnosis. High-performance liquid chromatography (HPLC), advancement in testing technology, is anticipated to propel market expansion because it yields data more quickly and accurately than conventional testing techniques. The market is anticipated to develop as a result of governmental initiatives and requirements for sickle cell anemia testing, particularly in newborns. Numerous nations have put in place newborn screening programmes for sickle cell anemia, which have aided in finding more cases of the condition and facilitating prompt treatment. In the upcoming years, the market is anticipated to develop due to rising healthcare costs and an increase in the number of healthcare facilities offering sickle cell anemia tests.

Lack of knowledge, however, can prevent the market from expanding. Many people, especially in underdeveloped nations, are unaware of sickle cell anemia or the value of screening and testing for it. Some people may find the cost of testing and screening to be a barrier, especially those who live in low-income areas. Limited access to healthcare: People may not have access to healthcare facilities that provide screening and testing for sickle cell anemia in some regions. Additionally, certain areas might not have access to the required reagents and diagnostic kits for testing and screening.

Sickle Cell Anemia Testing & Screening Market Insights

The sickle cell anemia testing & screening market is split into technology, age, sector, and regional segments. The technology category is divided into high-performance liquid chromatography, hemoglobin electrophoresis, isoelectric focusing, paper-based rapid diagnostics, lateral flow immunoassay, point-of-care tests, and other. By age, the segmentation includes adult screening (25 to 60 years), newborn screening (12 months and below), and other age groups (1 to 25 & above 60 years). Based on sector, the segmentation includes private labs, government labs, corporate labs, and others. Furthermore, the region segment is categorized into Latin America, North America, Europe, Asia-Pacific, and the Middle East & Africa.

Global Sickle Cell Anemia Testing & Screening Market Geographical Competition

Due to the number of newborn screening programmes that have been actively pushed out in North America, which has provided a favourable environment for key industry players, the region accounted for the largest revenue share of the worldwide sickle cell anaemia testing & screening market in 2021. All 50 US states and 8 Canadian provinces have implemented newborn screening programmes, creating a supportive climate for businesses operating in the market.

Recently, Asia-Pacific nations, particularly India, have seen an increase in knowledge of and acceptance for neonatal sickle cell screening. However, these affluent nations are putting strategies into place to deal with problems with prenatal screening in high-income countries and to simplify follow-up diagnosis or monitoring. In the near future, it would provide a significant boost to the Asia Pacific industry.

Global Sickle Cell Anemia Testing & Screening Industry Segment Analysis

Market By Technology

·         Hemoglobin Electrophoresis

·         High-performance Liquid Chromatography

·         Isoelectric focusing

·         Lateral Flow Immunoassay

·         Paper-Based Rapid Diagnostics

·         Point-of-Care Tests

·         Other

Market By Age

·         Newborn Screening (12 months and below)

·         Adult Screening (25 to 60 years)

·         Other Age Groups (1 to 25 & above 60 years)

Market By Sector

·         Government Labs

·         Corporate Labs

·         Private Labs

·         Others

Sickle Cell Anemia Testing & Screening Market Leading Companies

The players profiled in the report are BioMedomics Inc., Bio-Rad Laboratories, HEMEX HEALTH, Laboratory Corporation of America Holdings, PerkinElmer Inc., Quest Diagnostics, Silver Lake Research Corporation, and STRECK.

Sickle Cell Anemia Testing & Screening Market Regions